Dr. Patrice Hugo has been named vice president of scientific affairs for the global central lab network of
MDS Pharma Services. In this role, he will lead the development of innovative biomarkers and esoteric assays to enhance clinical development productivity from Phases I through IV.
"We're delighted to offer our clients access to Dr. Hugo's experience and expertise in the development and application of biomarkers," said MDS Pharma Services' president David Spaight. "The importance of biomarkers has grown as the industry shifts toward personalized medicine and seeks to expedite drug discovery and development while controlling costs. Dr. Hugo's appointment reflects our intention to remain a key player in this important arena."
Dr. Hugo has more than 15 years of relevant experience in discovery, preclinical, clinical development, diagnostics and biotechnology, with a focus on biomarker evaluation and development. His biomarker experience crosses various therapeutic areas including oncology, infectious disease, inflammation, metabolic disease, and women's health. He comes to MDS Pharma Services from Caprion Proteomics, where he was executive vice president, R&D. From 1997 to 2003, he was with PROCREA BioSciences, first as the vice president of scientific research and then as chief scientific officer.
Magazine
